Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
珊瑚癣净 (Shanhu Xuanjing) is a topical antifungal and antibacterial formulation developed and marketed by Shenqi Pharmaceutical. It is primarily indicated for the treatment of fungal skin infections, including tinea pedis (athlete's foot), tinea manuum (hand fungus), and onychomycosis (nail fungus). The formulation contains a combination of active ingredients: compound coral ginger tincture (derived from *Alpinia officinarum*), salicylic acid, and acetic acid. Salicylic acid and acetic acid provide keratolytic and antiseptic properties, helping to exfoliate infected skin layers and lower the local pH to inhibit microbial growth, while the coral ginger tincture contributes direct antifungal activity. It is typically administered as a soak, where the product is diluted with warm water and the affected area is immersed for approximately 30 minutes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 珊瑚癣净.